NASDAQ · XERS
Healthcare · Biotechnology
$10.11
Up+$0.04 (+0.40%)
Updated Oct 8, 2026, 11:16 AM
SID Score
7.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · XERS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
XERS closed at $10.11 after 21 trading sessions, up 31.13% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $10.00 | $10.27 | $9.91 | $10.11 | 2.22M |
| Oct 6, 2026 | $10.23 | $10.325 | $9.90 | $10.07 | 2.4M |
| Oct 5, 2026 | $9.15 | $10.235 | $9.12 | $10.13 | 4.66M |
| Oct 2, 2026 | $9.34 | $9.34 | $9.035 | $9.08 | 1.8M |
| Oct 1, 2026 | $9.52 | $9.69 | $9.175 | $9.25 | 3.59M |
| Sep 30, 2026 | $9.97 | $10.07 | $9.545 | $9.56 | 3.75M |
| Sep 29, 2026 | $9.77 | $11.33 | $9.50 | $9.98 | 19.31M |
| Sep 28, 2026 | $9.05 | $10.005 | $9.00 | $9.83 | 4.46M |
| Sep 25, 2026 | $8.99 | $9.15 | $8.8501 | $9.10 | 1.55M |
| Sep 24, 2026 | $8.65 | $8.995 | $8.56 | $8.95 | 1.36M |
| Sep 23, 2026 | $8.74 | $9.20 | $8.455 | $8.66 | 2.04M |
| Sep 22, 2026 | $8.90 | $8.97 | $8.64 | $8.73 | 1.69M |
| Sep 21, 2026 | $8.28 | $8.81 | $8.16 | $8.80 | 3.23M |
| Sep 18, 2026 | $8.10 | $8.25 | $7.93 | $8.20 | 4.71M |
| Sep 17, 2026 | $7.685 | $8.18 | $7.685 | $8.16 | 2.34M |
| Sep 16, 2026 | $7.50 | $7.92 | $7.50 | $7.78 | 2.04M |
| Sep 15, 2026 | $7.57 | $7.58 | $7.41 | $7.49 | 1.18M |
| Sep 14, 2026 | $7.595 | $7.685 | $7.52 | $7.57 | 2.01M |
| Sep 11, 2026 | $7.89 | $7.89 | $7.40 | $7.45 | 2.4M |
| Sep 10, 2026 | $7.80 | $7.99 | $7.63 | $7.67 | 1.96M |
| Sep 9, 2026 | $8.43 | $8.605 | $7.64 | $7.71 | 2.82M |
The latest Smart Investors Daily articles mentioning XERS.
Company
Market Activity
Research & News
XERS research
Company profile and research snapshot.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | Barclays | Overweight | — |
| Sep 10, 2026 | Leerink Partners | Outperform | — |
| Aug 20, 2026 | Barclays | Overweight | — |
| Mar 2, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 6, 2026
Xeris Biopharma Holdings (NASDAQ:XERS) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
Yahoo · Oct 2, 2026
CHICAGO, October 02, 2026--Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Yahoo · Sep 29, 2026
Investing.com -- H Lundbeck (LON:0ND5) has expressed interest in a potential takeover of Chicago-based commercial-stage drugmaker Xeris Pharmaceuticals Inc (NASDAQ:XERS), according to people familiar with the matter cited by Bloomberg. The Danish pharmaceutical group has been working with financial advisers to explore an acquisition of the U.S. firm, though discussions remain preliminary and may not result in a formal transaction.
Yahoo · Sep 29, 2026
According to a Bloomberg report, Danish company Lundbeck has been working with advisers to explore a potential takeover of Xeris.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XERS.
